Christine A. White - Concepedia

Author

Christine A. White

Also Known As

C WHITE, C. A. White, C. White, C.A. White, CA White, CHRISTINE A. WHITE, Carl W. White, Caroline White, Christine A White, Christine A. WHITE

205

Publications

Citations

H-Index

Concepts

All Affiliations

Queen's University University of Ottawa Ottawa Hospital Mayo Clinic Kingston Health Sciences Centre

About

Christine A. White is an author at Queen's University specializing in medicine, nephrology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	2K
2	Public Health	2	2	127
3	Business	1	1	11
4	Education	1	1	53
5	Health Sciences	1	1	183

Christine A. White

Publications

6.1K

Citations

H-Index

Page 1

	Year	Citations
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma David G. Maloney, Antonio J Grillo-López, Christine A. White, Blood	1997	1.7K
Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon, Journal of Clinical Oncology	2002	649
Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma Neil L. Berinstein, A.J. Grillo-López, Christine A. White, Annals of Oncology Anti-tumor ResponseLymphoid NeoplasiaHematological MalignancySerum RituximabMedicine	1998	520
Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma Thomas E. Witzig, Christine A. White, Leo I. Gordon, Journal of Clinical Oncology	2003	290
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial Gregory A. Wiseman, Leo I. Gordon, Pratik S. Multani, Blood	2002	266
Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma Gregory A. Wiseman, Christine A. White, Michael Stabin, European Journal of Nuclear Medicine and Molecular Imaging Lymphoid NeoplasiaRadioimmunotherapy Dosimetry ResultsPhase I/ii 90MedicineYttrium-90 Ibritumomab Tiuxetan	2000	234
The Chemokines, CX3CL1, CCL14, and CCL4, Promote Human Trophoblast Migration at the Feto-Maternal Interface1 Natalie J. Hannan, Rebecca L. Jones, Christine A. White, Biology of Reproduction Developmental BiologySignal TransductionHuman Embryo ImplantationFeto-maternal Interface1Cell Trafficking	2006	203
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma Auayporn Nademanee, Stephen J. Forman, Arturo Molina, Blood	2005	200
Estimating Glomerular Filtration Rate in Kidney Transplantation Christine A. White, Ayub Akbari, Naser Hussain, Journal of the American Society of Nephrology HemodialysisTranslational MedicineUrologyRenal FunctionKidney Transplant	2005	184
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Gregory A. Wiseman, Christine A. White, Richard Sparks, Critical Reviews in Oncology/Hematology Lymphoid NeoplasiaRadiation MedicineOncologyDosimetry ResultsRadiation Therapy	2001	183

Page 1